NasdaqGS - Delayed Quote
USD
Alnylam Pharmaceuticals, Inc. (ALNY)
266.11
+1.61
(+0.61%)
At close: September 4 at 4:00:01 PM EDT
263.16
-2.95
(-1.11%)
After hours: September 4 at 7:54:55 PM EDT
Trade ALNY on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for ALNY
- Previous Close
264.50 - Open
258.02 - Bid 243.01 x 100
- Ask 235.64 x 200
- Day's Range
258.02 - 266.85 - 52 Week Range
197.81 - 495.55 - Volume
1,420,329 - Avg. Volume
1,816,787 - Market Cap (intraday)
35.608B - Beta (5Y Monthly) 0.30
- PE Ratio (TTM)
46.36 - EPS (TTM)
5.74 - Earnings Date (est.) Oct 29, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
370.20
Recent News
View More
Performance Overview
Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
ALNY
33.08%
S&P 500 (^GSPC)
12.75%
1-Year Return
ALNY
41.33%
S&P 500 (^GSPC)
18.71%
3-Year Return
ALNY
32.28%
S&P 500 (^GSPC)
70.93%
5-Year Return
ALNY
34.77%
S&P 500 (^GSPC)
70.18%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 9/2/2026
-
Market Cap
35.78B
-
Enterprise Value
33.74B
-
Trailing P/E
46.59
-
Forward P/E
20.92
-
PEG Ratio (5yr expected)
0.35
-
Price/Sales (ttm)
7.72
-
Price/Book (mrq)
26.42
-
Enterprise Value/Revenue
7.02
-
Enterprise Value/EBITDA
30.53
Financial Highlights
Profitability and Income Statement
-
Profit Margin
16.13%
-
Return on Assets (ttm)
12.34%
-
Return on Equity (ttm)
96.56%
-
Revenue (ttm)
4.8B
-
Net Income Avi to Common (ttm)
774.71M
-
Diluted EPS (ttm)
5.74
Balance Sheet and Cash Flow
-
Total Cash (mrq)
3.31B
-
Total Debt/Equity (mrq)
220.62%
-
Levered Free Cash Flow (ttm)
271.54M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Alnylam Earnings: Shares Tank Amid Reduced Outlook for Key ATTR Franchise
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
RatingPrice Target -
Alnylam Earnings: Shares Tank Amid Reduced Outlook for Key ATTR Franchise
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
RatingPrice Target -
Alnylam Earnings: Amvuttra Uptake Drives Sales; Durability of Demand in Focus Amid Competition
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
RatingPrice Target -
Alnylam Earnings: Amvuttra Uptake Drives Sales; Durability of Demand in Focus Amid Competition
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
RatingPrice Target
